CADL (Candel Therapeutics, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by CADL officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-19 | Seshu Tyagarajan | Chief Technology Officer | Sell | — | — |
| 2026-07-08 | Mark E. Sims | Chief Commercial Officer | A | — | — |
| 2026-07-01 | Nicoletta Loggia | Director | A | — | — |
| 2026-07-01 | Francesca Barone | Chief Scientific Officer | Sell | — | — |
| 2026-07-01 | Seshu Tyagarajan | Chief Technology Officer | Sell | — | — |
| 2026-07-01 | Paul B Manning | Director | A | — | — |
| 2026-07-01 | JOSEPH C PAPA | Director | A | — | — |
| 2026-06-24 | Renee Gaeta | Director | A | — | — |
| 2026-06-24 | Gary J. Nabel | Director | A | — | — |
| 2026-06-24 | JOSEPH C PAPA | Director | A | — | — |
| 2026-06-24 | Christopher Martell | Director | A | — | — |
| 2026-06-24 | Paul B Manning | Director | A | — | — |
| 2026-06-24 | Nicoletta Loggia | Director | A | — | — |
| 2026-06-24 | Maha Radhakrishnan | Director | A | — | — |
| 2026-06-24 | Edward J. Benz JR | Director | A | — | — |
| 2026-06-24 | Diem Nguyen | Director | A | — | — |
| 2026-04-02 | JOSEPH C PAPA | Director | A | — | — |
| 2026-04-02 | Nicoletta Loggia | Director | A | — | — |
| 2026-04-02 | Paul B Manning | Director | A | — | — |
| 2026-02-26 | Paul B Manning | Director | Buy | — | — |
| 2026-01-28 | Seshu Tyagarajan | Chief Technology Officer | A | — | — |
| 2026-01-28 | Charles Schoch | Chief Financial Officer | A | — | — |
| 2026-01-28 | Francesca Barone | Chief Scientific Officer | A | — | — |
| 2026-01-28 | William Garrett Nichols | Chief Medical Officer | A | — | — |
| 2026-01-28 | Paul Peter Tak | Chief Executive Officer | A | — | — |
| 2025-07-30 | William Garrett Nichols | Chief Medical Officer | MIXED | — | — |
| 2025-07-02 | William Garrett Nichols | Chief Medical Officer | MIXED | — | — |
| 2025-06-26 | Charles Schoch | Chief Financial Officer | A | — | — |
| 2025-06-26 | Gary J. Nabel | Director | A | — | — |
| 2025-06-26 | Seshu Tyagarajan | Chief Technology Officer | A | — | — |
| 2025-06-26 | Nicoletta Loggia | Director | A | — | — |
| 2025-06-26 | Francesca Barone | Chief Scientific Officer | A | — | — |
| 2025-06-26 | Paul Peter Tak | Chief Executive Officer | A | — | — |
| 2025-06-26 | JOSEPH C PAPA | Director | A | — | — |
| 2025-06-26 | Christopher Martell | Director | A | — | — |
| 2025-06-26 | Paul B Manning | Director | A | — | — |
| 2025-06-24 | Charles Schoch | Chief Financial Officer | A | — | — |
| 2025-06-18 | Christopher Martell | Director | A | — | — |
| 2025-06-18 | Renee Gaeta | Director | A | — | — |
| 2025-06-18 | Nicoletta Loggia | Director | A | — | — |
| 2025-06-18 | Paul B Manning | Director | A | — | — |
| 2025-06-18 | JOSEPH C PAPA | Director | A | — | — |
| 2025-06-18 | Gary J. Nabel | Director | A | — | — |
| 2025-06-18 | Diem Nguyen | Director | A | — | — |
| 2025-06-18 | Edward J. Benz JR | Director | A | — | — |
| 2025-06-06 | Maha Radhakrishnan | Director | A | — | — |
| 2025-03-20 | William Garrett Nichols | Chief Medical Officer | MIXED | — | — |
| 2025-03-20 | Seshu Tyagarajan | Chief Technology Officer | MIXED | — | — |
| 2025-03-20 | Francesca Barone | Chief Scientific Officer | MIXED | — | — |
| 2025-03-20 | Paul Peter Tak | Chief Executive Officer | Sell | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 2,984,752 | — |
| — | Director | 411,564 | — |
| — | Chief Executive Officer | 268,566 | — |
| — | Chief Financial Officer | 202,009 | — |
| — | 10%+ Owner | 191,443 | — |
| — | 10%+ Owner | 180,861 | — |
| — | Director | 102,271 | — |
| — | Chief Scientific Officer | 77,362 | — |
| — | Chief Technology Officer | 76,865 | — |
| — | Chief Medical Officer | 52,493 | — |
| — | Chief Financial Officer | 43,391 | — |
| — | Chief Financial Officer | 10,125 | — |
| — | Director | 10,000 | — |
| — | Chief Business Officer | 6,000 | — |
| — | Director | 5,353 | — |
| — | Director | 2,141 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the CADL quote page; the site-wide leaderboard is on the insider transactions hub.